SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 28, Issue 7, 2010, Pages 1112-1116

Finasteride to prevent prostate cancer: Should all men or only a high-risk subgroup be treated?

(3) Vickers, Andrew J a Savage, Caroline J a Lilja, Hans a

a MEMORIAL SLOAN KETTERING CANCER CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ENZYME INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK BENEFIT ANALYSIS; RISK REDUCTION; BLOOD; DECISION SUPPORT SYSTEM; MIDDLE AGED; PROSTATE TUMOR; RISK;

AGED; DECISION SUPPORT TECHNIQUES; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK;

EID: 77949877667 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2009.23.5572 Document Type: Article

Times cited : (21)

References (18)

1
- 0037812658
- The influence of finasteride on the development of prostate cancer
- DOI 10.1056/NEJMoa030660
- Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003 (Pubitemid 36859473)
- (2003) New England Journal of Medicine , vol.349 , Issue.3 , pp. 215-224
- Thompson, I.M.¹ Goodman, P.J.² Tangen, C.M.³ Lucia, M.S.⁴ Miller, G.J.⁵ Ford, L.G.⁶ Lieber, M.M.⁷ Cespedes, R.D.⁸ Atkins, J.N.⁹ Lippman, S.M.¹⁰ Carlin, S.M.¹¹ Ryan, A.¹² Szczepanek, C.M.¹³ Crowley, J.J.¹⁴ Coltman Jr., C.A.¹⁵

2
- 33747174509
- Finasteride as a chemopreventive agent in prostate cancer: Impact of the PCPT on urologic practice
- DOI 10.1038/ncpuro0574, PII NCPURO0574
- Goetzl MA, Holzbeierlein JM: Finasteride as a chemopreventive agent in prostate cancer: Impact of the PCPT on urologic practice. Nat Clin Pract Urol 3:422-429, 2006 (Pubitemid 44226919)
- (2006) Nature Clinical Practice Urology , vol.3 , Issue.8 , pp. 422-429
- Goetzl, M.A.¹ Holzbeierlein, J.M.²

3
- 30344463849
- Evidence for a biopsy derived grade artifact among larger prostate glands
- DOI 10.1016/S0022-5347(05)00236-3, PII S0022534705002363
- Kulkarni GS, Al-Azab R, Lockwood G, et al: Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175:505-509, 2006 (Pubitemid 43067339)
- (2006) Journal of Urology , vol.175 , Issue.2 , pp. 505-509
- Kulkarni, G.S.¹ Al-Azab, R.² Lockwood, G.³ Toi, A.⁴ Evans, A.⁵ Trachtenberg, J.⁶ Jewett, M.A.S.⁷ Finelli, A.⁸ Fleshner, N.E.⁹

4
- 34748863567
- Finasteride and high-grade prostate cancer in the prostate cancer prevention trial
- DOI 10.1093/jnci/djm117
- Lucia MS, Epstein JI, Goodman PJ, et al: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:1375-1383, 2007 (Pubitemid 351767184)
- (2007) Journal of the National Cancer Institute , vol.99 , Issue.18 , pp. 1375-1383
- Lucia, M.S.¹ Epstein, J.I.² Goodman, P.J.³ Darke, A.K.⁴ Reuter, V.E.⁵ Civantos, F.⁶ Tangen, C.M.⁷ Parnes, H.L.⁸ Lippman, S.M.⁹ La, R.F.G.¹⁰ Kattan, M.W.¹¹ Crawford, E.D.¹² Ford, L.G.¹³ Coltman, C.A.¹⁴ Thompson, I.M.¹⁵

5
- 67650874081
- Cancer statistics, 2009
- Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-49, 2009
- (2009) CA Cancer J Clin , vol.59 , pp. 225-249
- Jemal, A.¹ Siegel, R.² Ward, E.³

6
- 34447293054
- Longitudinal analysis of sexual function reported by men in the prostate cancer prevention Trial
- DOI 10.1093/jnci/djm023, Pdf Contents
- Moinpour CM, Darke AK, Donaldson GW, et al: Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:1025-1035, 2007 (Pubitemid 47232603)
- (2007) Journal of the National Cancer Institute , vol.99 , Issue.13 , pp. 1025-1035
- Moinpour, C.M.¹ Darke, A.K.² Donaldson, G.W.³ Thompson Jr., I.M.⁴ Langley, C.⁵ Ankerst, D.P.⁶ Patrick, D.L.⁷ Ware Jr., J.E.⁸ Ganz, P.A.⁹ Shumaker, S.A.¹⁰ Lippman, S.M.¹¹ Coltman Jr., C.A.¹²

7
- 39749113833
- Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis
- DOI 10.1002/cncr.23276
- Svatek RS, Lee JJ, Roehrborn CG, et al: Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis. Cancer 112: 1058-1065, 2008 (Pubitemid 351304590)
- (2008) Cancer , vol.112 , Issue.5 , pp. 1058-1065
- Svatek, R.S.¹ Lee, J.J.² Roehrborn, C.G.³ Lippman, S.M.⁴ Lotan, Y.⁵

8
- 33846959137
- Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years
- DOI 10.1200/JCO.2006.06.9351
- Lilja H, Ulmert D, Björk T, et al: Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 25:431-436, 2007 (Pubitemid 350002992)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.4 , pp. 431-436
- Lilja, H.¹ Ulmert, D.² Bjork, T.³ Becker, C.⁴ Serio, A.M.⁵ Nilsson, J.-A.⁶ Abrahamsson, P.-A.⁷ Vickers, A.J.⁸ Berglund, G.⁹

9
- 41149091657
- Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
- Ulmert D, Cronin AM, Björk T, et al: Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. BMC Med 6:6, 2008
- (2008) BMC Med , vol.6 , pp. 6
- Ulmert, D.¹ Cronin, A.M.² Björk, T.³

10
- 33750219137
- Selecting patients for randomized trials: A systematic approach based on risk group
- Vickers AJ, Kramer BS, Baker SG. Selecting patients for randomized trials: a systematic approach based on risk group. Trials 7:30, 2006
- (2006) Trials , vol.7 , pp. 30
- Vickers, A.J.¹ Kramer, B.S.² Baker, S.G.³

11
- 76749139644
- Fast Stats: An interactive tool for access to SEER cancer statistics: Surveillance Research Program, National Cancer Institute. http://seer.cancer. gov/faststats
- Fast Stats: An Interactive Tool for Access to SEER Cancer Statistics: Surveillance Research Program, National Cancer Institute

12
- 37448998966
- Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent
- Kattan MW, Cuzick J, Fisher G, et al: Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 112:69-74, 2008
- (2008) Cancer , vol.112 , pp. 69-74
- Kattan, M.W.¹ Cuzick, J.² Fisher, G.³

13
- 41149168617
- Is it necessary to detect all prostate cancers in men with serum PSA levels < 3.0 ng/mL? A comparison of biopsy results of PCPT and outcome-related information from ERSPC
- Schröder FH, Bangma CH, Roobol MJ: Is it necessary to detect all prostate cancers in men with serum PSA levels < 3.0 ng/mL? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 53:901-908, 2008
- (2008) Eur Urol , vol.53 , pp. 901-908
- Schröder, F.H.¹ Bangma, C.H.² Roobol, M.J.³

14
- 57649136472
- Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: A simulation study
- Cronin AM, Vickers AJ: Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: A simulation study. BMC Med Res Methodol 8:75, 2008
- (2008) BMC Med Res Methodol , vol.8 , pp. 75
- Cronin, A.M.¹ Vickers, A.J.²

15
- 33747407318
- Effect of finasteride on the sensitivity of PSA for detecting prostate cancer
- DOI 10.1093/jnci/djj307
- Thompson IM, Chi C, Ankerst DP, et al: Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98:1128-1133, 2006 (Pubitemid 44288787)
- (2006) Journal of the National Cancer Institute , vol.98 , Issue.16 , pp. 1128-1133
- Thompson, I.M.¹ Chi, C.² Ankerst, D.P.³ Goodman, P.J.⁴ Tangen, C.M.⁵ Lippman, S.M.⁶ Lucia, M.S.⁷ Parnes, H.L.⁸ Coltman, C.A.⁹

16
- 33947170033
- A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate
- DOI 10.1016/j.clinthera.2007.01.018, PII S014929180700032X
- Naslund MJ, Miner M: A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 29:17-25, 2007 (Pubitemid 46414037)
- (2007) Clinical Therapeutics , vol.29 , Issue.1 , pp. 17-25
- Naslund, M.J.¹ Miner, M.²

17
- 8844239174
- The fallacy of enrolling only high-risk subjects in cancer prevention trials: Is there a "free lunch"?
- Baker SG, Kramer BS, Corle D: The fallacy of enrolling only high-risk subjects in cancer prevention trials: Is there a "free lunch"? BMC Med ResMethodol 4:24, 2004
- (2004) BMC Med ResMethodol , vol.4 , pp. 24
- Baker, S.G.¹ Kramer, B.S.² Corle, D.³

18
- 42949137472
- Does the level of prostate cancer risk affect cancer prevention with finasteride?
- Thompson IM, Tangen CM, Parnes HL, et al: Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology 71:854-857, 2008
- (2008) Urology , vol.71 , pp. 854-857
- Thompson, I.M.¹ Tangen, C.M.² Parnes, H.L.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.